Lipid-altering efficacy of switching to ezetimibe/simvastatin 10/20 mg versus
rosuvastatin 10 mg in high-risk patients with and without metabolic syndrome.
Author(s): Averna M, Missault L, Vaverkova H, Farnier M, Viigimaa M, Dong Q, Shah A,
Johnson-Levonas AO, Taggart W, Brudi P.
Affiliation(s): Professor of Internal Medicine, Department of Clinical Medicine and Emerging
Diseases, University of Palermo-Medical School, Palermo, Italy. avernam@unipa.it
Publication date & source: 2011, Diab Vasc Dis Res. , 8(4):262-70
Metabolic syndrome (MetS) is a clustering of atherosclerotic coronary heart
disease risk factors. This post-hoc analysis compared the effects of switching to
ezetimibe/simvastatin 10/20 mg or rosuvastatin 10 mg in a cohort of 618 high-risk
hypercholesterolaemic patients with (n=368) and without (n=217) MetS who had
previously been on statin monotherapy. Patients were randomised 1:1 to
double-blind ezetimibe/simvastatin 10/20 mg or rosuvastatin 10 mg for 6 weeks.
Least squares mean percent change from baseline and 95% confidence intervals in
lipid efficacy parameters were calculated for the population and within
subgroups. Treatment with ezetimibe/simvastatin was significantly more effective
than rosuvastatin at lowering low-density lipoprotein cholesterol, total
cholesterol, non- high-density lipoprotein cholesterol, and apolipoprotein B (all
p<0.001). No significant differences in treatment effects were seen between the
presence and absence of MetS. In this post-hoc analysis of high-risk
hypercholesterolaemic patients the lipid-reducing effects of
ezetimibe/simvastatin or rosuvastatin were not altered significantly by the
presence of MetS.
|